Ms. O’Connell, who is in charge of the Administration for Strategic Preparedness and Response, wrote in an Aug. 30 blog post that “it has been more than 530 days since we last received new funding for COVID-19.” Because of this, she predicts the administration will be forced to forgo buying and delivering free shots by January and that the last supply of Pfizer’s antiviral treatment will dry up by mid-2023.
The supply of Evusheld, AstraZeneca’s preventative treatment, and Lagevrio, Merck’s antiviral drug, will run out by early 2023, she said.
Other free COVID-19 response measures, including at-home COVID-19 test kits, will end Sept. 2 because of the shrinking budget.
Ms. O’Connell said “additional COVID-19 funding continues to be urgently needed” for the updated boosters expected to be ready early September and other “critical response needs.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.